Utilization Patterns of Amantadine in Parkinson’s Disease Patients Enrolled in the French COPARK Study

Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia

(2018) Santiago Perez-Lloret et al.   JOURNAL OF NEURAL TRANSMISSION

International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease

(2018) Susan H. Fox et al.   MOVEMENT DISORDERS

Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3)

(2017) Wolfgang Oertel et al.   MOVEMENT DISORDERS

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study)

(2017) Rajesh Pahwa et al.   JAMA Neurology

Trends in inpatient antiparkinson drug use in the USA, 2001–2012

(2015) James A. G. Crispo et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Falls in ambulatory non-demented patients with Parkinson’s disease

(2015) Olivier Rascol et al.   JOURNAL OF NEURAL TRANSMISSION

Parkinson's disease

(2015) Lorraine V Kalia et al.   LANCET

Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)

(2015) Rajesh Pahwa et al.   MOVEMENT DISORDERS

Prevalence, Determinants, and Effect on Quality of Life of Freezing of Gait in Parkinson Disease

(2014) Santiago Perez-Lloret et al.   JAMA Neurology

Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial

(2013) F. Ory-Magne et al.   NEUROLOGY

Systematic review of levodopa dose equivalency reporting in Parkinson's disease

(2010) Claire L. Tomlinson et al.   MOVEMENT DISORDERS